Facing the challenges of hepatitis B management in a developing country

Journal of Infection in Developing Countries

Volumn 6, Issue 3, 2012, Pages 299-300

  Oluyemi, Aderemi ^a   Odeghe, Emuobor ^b  

^a Ikeja GRA   (Nigeria)

^b Premier Hospital   (Nigeria)

Author keywords

Developing countries; Hepatitis B virus; Hyperendemic zone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2 INTERFERON; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AWARENESS; CASE REPORT; DEVELOPING COUNTRY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LETTER; MALE; TREATMENT DURATION;

HEPATITIS B VIRUS;

EID: 84858422732     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.2358     Document Type: Letter

References (2)

1. Sirisena ND, Njoku MO, Idoko JA, Isamade E, Barau C, Jelpe D, Zamani A, Otowo S (2002) Carriage rate of hepatitis-B surface antigen (HBsAg) in an urban community in Jos, Plateau State, Nigeria. Niger Postgrad Med J 9: 7-10.
2. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A metaanalysis. Ann Intern Med 119: 312-323.